CoChat

Integration of a fasting-mimicking diet programme in primary care for type 2 diabetes reduces the need for medication and improves glycaemic control: a 12-month randomised controlled trial

Open access
van den Burg, Elske L., Schoonakker, Marjolein P., van Peet, Petra G., van den Akker-van Marle, Elske M., Lamb, Hildo J., Longo, Valter D., Numans, Mattijs E., Pijl, Hanno · 2024 · Diabetologia

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Aims/hypothesis: The aim of this study was to evaluate the impact on metabolic control of periodic use of a 5-day fasting-mimicking diet (FMD) programme as an adjunct to usual care in people with type 2 diabetes under regular primary care surveillance. Methods: In this randomised, controlled, assessor-blinded trial, people with type 2 diabetes using metformin as the only glucose-lowering drug and/or diet for glycaemic control were randomised to receive 5-day cycles of an FMD monthly as an adjunct to regular care by their general practitioner or to receive regular care only. The primary outcomes were changes in glucose-lowering medication (as reflected by the medication effect score) and HbA 1c levels after 12 months. Moreover, changes in use of glucose-lowering medication and/or HbA 1c levels in individual participants were combined to yield a clinically relevant outcome measure (‘glycaemic management’), which was categorised as improved, stable or deteriorated after 1 year of follow-up. Several secondary outcome measures were also examined, including changes in body weight. Results: One hundred individuals with type 2 diabetes, age 18–75 years, BMI ≥27 kg/m 2, were randomised to the FMD group (n=51) or the control group (n=49). Eight FMD participants and ten control participants were lost to follow-up. Intention-to-treat analyses, using linear mixed models, revealed adjusted estimated treatment effects for the medication effect score (−0.3; 95% CI −0.4, −0.2; p<0.001), HbA 1c (−3.2 mmol/mol; 95% CI −6.2, −0.2 and −0.3%; 95% CI −0.6, −0.0; p=0.04) and body weight (−3.6 kg; 95% CI −5.2, −2.1; p<0.001) at 12 months. Glycaemic management improved in 53% of participants using FMD vs 8% of control participants, remained stable in 23% vs 33%, and deteriorated in 23% vs 59% (p<0.001). Conclusions/interpretation: Integration of a monthly FMD programme in regular primary care for people with type 2 diabetes who use metformin as the only glucose-lowering drug and/or diet for glycaemic control reduces the need for glucose-lowering medication, improves HbA 1c despite the reduction in medication use, and appears to be safe in routine clinical practice. Trial registration: ClinicalTrials.gov NCT03811587 Funding: The project was co-funded by Health~Holland, Top Sector Life Sciences & Health, the Dutch Diabetes Foundation and L-Nutra. Graphical Abstract:

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-024-06137-0

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Study flow chart. na indicates the number of participants for whom this was the reason for being lost to follow-up or discontinuing FMD; there may be several reasons per participant
Fig. 1 Study flow chart. na indicates the number of participants for whom this was the reason for being lost to follow-up or discontinuing FMD; there may be several reasons per participantCC BY · PubMed Central
Fig. 2 Change over time in total MES, HbA1c and HbA1c corrected for medication use by adding total MES for the FMD group and the control group (ITT analysis). Values are means ± SEM at baseline, 6 months and 12 months. The numbers of participants per timepoint and per group are shown in Table 3. (a) Change in MES over time. (b) Change in HbA1c (mmol/mol) over time. (c) Change in HbA1c (%) over time. (d) Change in HbA1c corrected for the total MES over time. *p<0.05; **p<0.01; ***p<0.001 vs the control group
Fig. 2 Change over time in total MES, HbA1c and HbA1c corrected for medication use by adding total MES for the FMD group and the control group (ITT analysis). Values are means ± SEM at baseline, 6 months and 12 months. The numbers of participants per timepoint and per group are shown in Table 3. (a) Change in MES over time. (b) Change in HbA1c (mmol/mol) over time. (c) Change in HbA1c (%) over time. (d) Change in HbA1c corrected for the total MES over time. *p<0.05; **p<0.01; ***p<0.001 vs the control groupCC BY · PubMed Central
Fig. 3 Effect of the FMD on use of glucose-lowering medication and HbA1c levels in participants in the FMD group and the control group at 12 months (ITT analysis). Bars represent the percentage of participants in each category (total n=43 in the FMD group vs n=39 in the control group). Differences between the FMD group and the control group were evaluated using χ2 test. The categories are defined in Table 1. (a) Change in use of glucose-lowering medication at the end of the study compared with baseline. (b) Change in HbA1c at the end of the study compared with baseline. (c) Glycaemic management at the end of the study compared with baseline
Fig. 3 Effect of the FMD on use of glucose-lowering medication and HbA1c levels in participants in the FMD group and the control group at 12 months (ITT analysis). Bars represent the percentage of participants in each category (total n=43 in the FMD group vs n=39 in the control group). Differences between the FMD group and the control group were evaluated using χ2 test. The categories are defined in Table 1. (a) Change in use of glucose-lowering medication at the end of the study compared with baseline. (b) Change in HbA1c at the end of the study compared with baseline. (c) Glycaemic management at the end of the study compared with baselineCC BY · PubMed Central
Fig. 4 Overview of glucose-lowering medication used at baseline and after 12 months in the FMD group and the control group (ITT analysis). (a) Use of glucose-lowering medication in the FMD group at baseline (n=43). (b) Use of glucose-lowering medication in the control group at baseline (n=39). (c) Use of glucose-lowering medication in the FMD group after 12 months (n=43). (d) Use of glucose-lowering medication in the control group after 12 months (n=39). DPP4 inhibitor, dipeptidyl peptidase-4 inhibitor; GLP-1 agonist, glucagon-like peptide-1 agonist
Fig. 4 Overview of glucose-lowering medication used at baseline and after 12 months in the FMD group and the control group (ITT analysis). (a) Use of glucose-lowering medication in the FMD group at baseline (n=43). (b) Use of glucose-lowering medication in the control group at baseline (n=39). (c) Use of glucose-lowering medication in the FMD group after 12 months (n=43). (d) Use of glucose-lowering medication in the control group after 12 months (n=39). DPP4 inhibitor, dipeptidyl peptidase-4 inhibitor; GLP-1 agonist, glucagon-like peptide-1 agonistCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 25

Metadata

Authors
van den Burg, E. L., Schoonakker, M. P., van Peet, P. G., van den Akker-van Marle, E. M., Lamb, H. J., Longo, V. D., Numans, M. E., & Pijl, H.
Affiliations
  • Leiden University Medical Center (NL)
  • University of Southern California (US)
Venue
Diabetologia
Published
2024-03-28
Volume
67
Issue
7
Pages
1245-1259
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W4393258687
Cited by
25
References
32
Citations by year
2026: 8 · 2025: 10 · 2024: 7
FWCI
7.06
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetologia (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Leiden Repository (Leiden University) (submittedVersion, cc-by)
Funders
  • L-Nutra
  • Diabetes Fonds
  • Health~Holland
Topics
  • Health Sciences › Medicine › Physiology (medical) › Dietary Effects on Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
fasting-mimicking diet, type 2 diabetes, glycemic control, HbA1c, metformin, primary care, body weight, intermittent fasting, weight loss, metabolic control, cost-effectiveness, quality of life
MeSH terms
Glycemic Control, Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Fasting, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Primary Health Care, Treatment Outcome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Integration of a fasting-mimicking diet programme in primary care for type 2 diabetes reduces the need for medication and improves glycaemic control: a 12-month randomised controlled trial. https://app.cochat.ai/papers/10.1007/s00125-024-06137-0
The paper
van den Burg, E. L., Schoonakker, M. P., van Peet, P. G., van den Akker-van Marle, E. M., Lamb, H. J., Longo, V. D., Numans, M. E., & Pijl, H. (2024). Integration of a fasting-mimicking diet programme in primary care for type 2 diabetes reduces the need for medication and improves glycaemic control: a 12-month randomised controlled trial. Diabetologia. https://doi.org/10.1007/s00125-024-06137-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.